OIL & GAS
RENEWABLE & ENVIRONMENT
ENGINEERING & CONTRUCTING
COMMUNICATIONS & INFORMATION TECHNOLOGY
Joseph and Gionis, LLC (Newport Beach, California USA) is a premier biotechnology consulting and distribution firm which is dedicated to promoting excellence of product service, biotechnology, health and welfare throughout the Middle East. Our products excel on the cutting edge of science and technology to promote health and well-being. Joseph and Gionis, LLC, is a duly authorized and registered limited liability company in the State of California. The company is wholly owned and operated by Thomas A. Gionis, MD JD LLM MBA MHA FICS FRCS and Dr. Walid Yousef who serves as President for International Affairs.
Joseph and Gionis, LLC, has extensive experience in international governmental affairs, international law, international business, international capital trade, and maintains active international contacts with the governments of various nations, public and private commercial enterprises, strategic investment groups and industrialists throughout the Middle East. As a result, Joseph and Gionis, LLC, has been instrumental in developing and maintaining numerous international business projects which have materialized into mutually beneficial international investment opportunities in the commercial and industrial marketplaces.
Oculus Innovative Sciences (www.oculusis.com) develops, manufactures and markets a family of products based upon the Microcyn ®Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care, high disinfectant solution and others. Microcyn Technology has received seven (7) FDA Approvals and CE Mark for use in different applications. The Microcyn Technology features a biocompatible, shelf-stable solution of 24 months that is currently commercialized in the United States, Europe, India, China, Mexico, U.A.E. and other Middle East countries.
Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA, VRE and E-Coli), viruses, fungi and spores; by increasing blood flow to the wound site; and reducing both inflammation and pain while assisting in faster wound closure.
Oculus has developed and manufactured and marketed a family of products intended to help prevent and treat infections in chronic and acute wounds. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. Our platform technology, Microcyn, is a non-toxic, super-oxidized water-based solution that is designed to treat a wide range of pathogens including, viruses, fungi, spores and antibiotic resistant strains of bacteria such as Methicillin-resistant Staphylococcus aureus, or MRSA, and Vancomycin-resistant Enterococcus, VRE, in wounds. In clinical testing and studies, our products were effective against a wide range of pathogens and were found to be non-toxic, easy to use and complementary to most existing treatment methods in wound care. Our experience and clinical data include that the use of Microcyn may shorten hospital stays, lower aggregate patient care costs and, in many cases, reduce the need for systemic antibiotics. Microcyn also has potential applications in several other large markets including respiratory, dermatology, disinfectant, dental and veterinary markets.
Microcyn provides significant advantages over current methods of care in the treatment of a wide range of chronic and acute wounds throughout all stages of treatment. Microcyn is the first topical product that is effective against a broad range of bacteria and other infectious microbes, including antibiotic resistant strains, such as MRSA, E-Coli and VRE, without causing toxic side effects on, or irritation of healthy tissue. Unlike, most antibiotics, Microcyn does not target specific strains of bacteria, a practice which has been shown to promote the development of resistant bacteria. In addition, our products are shelf stable and require no special preparation and are easy to use.